1
|
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.
|
Science
|
2010
|
9.61
|
2
|
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.
|
PLoS One
|
2009
|
8.37
|
3
|
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
|
N Engl J Med
|
2004
|
6.87
|
4
|
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
|
N Engl J Med
|
2003
|
5.79
|
5
|
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
|
Clin Infect Dis
|
2008
|
5.20
|
6
|
Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.
|
Clin Infect Dis
|
2008
|
5.14
|
7
|
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.
|
Clin Infect Dis
|
2003
|
4.51
|
8
|
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.
|
AIDS
|
2007
|
3.94
|
9
|
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.
|
J Infect Dis
|
2007
|
3.75
|
10
|
Update of the drug resistance mutations in HIV-1: Spring 2008.
|
Top HIV Med
|
2008
|
3.66
|
11
|
Update of the drug resistance mutations in HIV-1: December 2009.
|
Top HIV Med
|
2009
|
3.52
|
12
|
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
|
Ann Intern Med
|
2014
|
3.48
|
13
|
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.
|
Clin Infect Dis
|
2005
|
3.47
|
14
|
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.
|
PLoS One
|
2009
|
3.40
|
15
|
Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases.
|
Ann Intern Med
|
2014
|
3.24
|
16
|
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
|
JAMA
|
2006
|
3.23
|
17
|
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.
|
JAMA
|
2011
|
3.08
|
18
|
Update of the drug resistance mutations in HIV-1: Fall 2006.
|
Top HIV Med
|
2006
|
3.06
|
19
|
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
|
Clin Infect Dis
|
2007
|
3.05
|
20
|
Update of the Drug Resistance Mutations in HIV-1.
|
Top HIV Med
|
2008
|
2.91
|
21
|
Update of the drug resistance mutations in HIV-1: December 2010.
|
Top HIV Med
|
2010
|
2.91
|
22
|
Update of the drug resistance mutations in HIV-1: 2007.
|
Top HIV Med
|
2007
|
2.79
|
23
|
Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency.
|
J Clin Microbiol
|
2006
|
2.45
|
24
|
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
|
J Infect Dis
|
2010
|
2.45
|
25
|
Accuracy of the TRUGENE HIV-1 genotyping kit.
|
J Clin Microbiol
|
2003
|
2.32
|
26
|
Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).
|
AIDS
|
2011
|
2.22
|
27
|
Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation.
|
J Infect Dis
|
2013
|
2.17
|
28
|
Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370.
|
Antivir Ther
|
2002
|
2.07
|
29
|
Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions.
|
J Infect Dis
|
2010
|
2.05
|
30
|
Update of the drug resistance mutations in HIV-1: Fall 2005.
|
Top HIV Med
|
2005
|
2.04
|
31
|
Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease.
|
AIDS
|
2002
|
2.02
|
32
|
Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).
|
J Virol
|
2004
|
1.91
|
33
|
Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial.
|
J Acquir Immune Defic Syndr
|
2007
|
1.90
|
34
|
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
|
J Acquir Immune Defic Syndr
|
2005
|
1.87
|
35
|
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject.
|
J Virol
|
2008
|
1.84
|
36
|
Update of the Drug Resistance Mutations in HIV-1: 2005.
|
Top HIV Med
|
2005
|
1.83
|
37
|
In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA.
|
J Virol
|
2005
|
1.80
|
38
|
Challenges in clinical trial design for HIV-1 cure research.
|
Lancet
|
2013
|
1.74
|
39
|
Outcomes after virologic failure of first-line ART in South Africa.
|
AIDS
|
2010
|
1.74
|
40
|
Drug resistance mutations in HIV-1.
|
Top HIV Med
|
2003
|
1.72
|
41
|
Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy.
|
Clin Infect Dis
|
2010
|
1.72
|
42
|
Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR.
|
J Virol Methods
|
2012
|
1.65
|
43
|
Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095.
|
J Acquir Immune Defic Syndr
|
2007
|
1.64
|
44
|
Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
|
J Infect Dis
|
2006
|
1.62
|
45
|
Update of the drug resistance mutations in HIV-1: 2004.
|
Top HIV Med
|
2004
|
1.62
|
46
|
Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.
|
J Infect Dis
|
2009
|
1.61
|
47
|
High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen.
|
AIDS
|
2012
|
1.60
|
48
|
Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.
|
Clin Infect Dis
|
2010
|
1.53
|
49
|
Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance.
|
J Acquir Immune Defic Syndr
|
2005
|
1.52
|
50
|
Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure.
|
AIDS
|
2012
|
1.52
|
51
|
Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis.
|
J Acquir Immune Defic Syndr
|
2006
|
1.49
|
52
|
Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals.
|
J Acquir Immune Defic Syndr
|
2004
|
1.48
|
53
|
Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.
|
Clin Infect Dis
|
2005
|
1.47
|
54
|
Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy.
|
J Infect Dis
|
2011
|
1.45
|
55
|
In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine.
|
J Virol
|
2008
|
1.45
|
56
|
Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations.
|
J Virol Methods
|
2007
|
1.43
|
57
|
A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128.
|
HIV Clin Trials
|
2003
|
1.42
|
58
|
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
|
Curr Opin HIV AIDS
|
2009
|
1.41
|
59
|
Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults.
|
Antimicrob Agents Chemother
|
2008
|
1.39
|
60
|
Drug resistance mutations in HIV-1.
|
Top HIV Med
|
2004
|
1.37
|
61
|
Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure.
|
PLoS Pathog
|
2011
|
1.32
|
62
|
Enumeration of CD4+ T-cells using a portable microchip count platform in Tanzanian HIV-infected patients.
|
PLoS One
|
2011
|
1.32
|
63
|
Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.
|
J Virol
|
2006
|
1.32
|
64
|
Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa.
|
PLoS One
|
2012
|
1.31
|
65
|
Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.
|
J Acquir Immune Defic Syndr
|
2010
|
1.30
|
66
|
Quantum dot-based HIV capture and imaging in a microfluidic channel.
|
Biosens Bioelectron
|
2009
|
1.27
|
67
|
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248.
|
J Infect Dis
|
2013
|
1.26
|
68
|
Rapid automated cell quantification on HIV microfluidic devices.
|
Lab Chip
|
2009
|
1.25
|
69
|
Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
|
J Infect Dis
|
2005
|
1.25
|
70
|
The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption.
|
AIDS
|
2016
|
1.25
|
71
|
Chemokine antagonists as therapeutics: focus on HIV-1.
|
Annu Rev Med
|
2007
|
1.24
|
72
|
AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein.
|
J Infect Dis
|
2010
|
1.24
|
73
|
Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
|
J Acquir Immune Defic Syndr
|
2007
|
1.20
|
74
|
Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.
|
J Virol
|
2011
|
1.19
|
75
|
The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
|
Antimicrob Agents Chemother
|
2005
|
1.18
|
76
|
Efficient on-chip isolation of HIV subtypes.
|
Lab Chip
|
2012
|
1.17
|
77
|
A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115.
|
Antivir Ther
|
2007
|
1.17
|
78
|
Monitoring HIV treatment in developing countries.
|
BMJ
|
2006
|
1.13
|
79
|
Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia.
|
Antimicrob Agents Chemother
|
2012
|
1.13
|
80
|
The impact of the President's Emergency Plan for AIDS Relief (PEPfAR) beyond HIV and why it remains essential.
|
Clin Infect Dis
|
2010
|
1.12
|
81
|
Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL.
|
PLoS One
|
2012
|
1.10
|
82
|
Clinical implications of HIV-1 minority variants.
|
Clin Infect Dis
|
2013
|
1.09
|
83
|
Acute on-chip HIV detection through label-free electrical sensing of viral nano-lysate.
|
Small
|
2013
|
1.07
|
84
|
Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary.
|
J Infect Dis
|
2007
|
1.07
|
85
|
HIV-1 entry inhibitors: recent development and clinical use.
|
Curr Opin Virol
|
2013
|
1.07
|
86
|
Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood.
|
ACS Nano
|
2013
|
1.07
|
87
|
The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates.
|
J Virol Methods
|
2010
|
1.06
|
88
|
Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia.
|
AIDS
|
2011
|
1.05
|
89
|
Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.
|
Nanomedicine (Lond)
|
2010
|
1.05
|
90
|
HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course.
|
J Acquir Immune Defic Syndr
|
2003
|
1.05
|
91
|
Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence.
|
J Pharmacokinet Pharmacodyn
|
2006
|
1.05
|
92
|
Emerging technologies for point-of-care management of HIV infection.
|
Annu Rev Med
|
2014
|
1.05
|
93
|
Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.
|
J Acquir Immune Defic Syndr
|
2010
|
1.04
|
94
|
Design issues in initial HIV-treatment trials: focus on ACTG A5095.
|
Antivir Ther
|
2006
|
1.04
|
95
|
Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals.
|
AIDS Res Hum Retroviruses
|
2010
|
1.04
|
96
|
Tropism testing in the clinical management of HIV-1 infection.
|
Curr Opin HIV AIDS
|
2009
|
1.03
|
97
|
Continued evolution in gp41 after interruption of enfuvirtide in subjects with advanced HIV type 1 disease.
|
AIDS Res Hum Retroviruses
|
2006
|
0.99
|
98
|
Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.
|
J Infect Dis
|
2012
|
0.97
|
99
|
Simple filter microchip for rapid separation of plasma and viruses from whole blood.
|
Int J Nanomedicine
|
2012
|
0.97
|
100
|
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.
|
Clin Infect Dis
|
2009
|
0.96
|
101
|
Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.
|
J Acquir Immune Defic Syndr
|
2010
|
0.96
|
102
|
Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.
|
J Infect Dis
|
2008
|
0.96
|
103
|
Resistance in pediatric patients experiencing virologic failure with first-line and second-line antiretroviral therapy.
|
Pediatr Infect Dis J
|
2013
|
0.96
|
104
|
Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study.
|
AIDS
|
2014
|
0.94
|
105
|
HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
|
J Virol
|
2011
|
0.94
|
106
|
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
|
Top HIV Med
|
2009
|
0.93
|
107
|
Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C.
|
Virology
|
2012
|
0.93
|
108
|
Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
|
Antivir Ther
|
2011
|
0.92
|
109
|
Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide.
|
J Acquir Immune Defic Syndr
|
2008
|
0.92
|
110
|
HIV-1 subtype as a determinant of disease progression.
|
J Infect Dis
|
2008
|
0.92
|
111
|
Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.
|
AIDS
|
2010
|
0.92
|
112
|
Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial.
|
J Infect Dis
|
2011
|
0.91
|
113
|
Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy.
|
Antivir Ther
|
2007
|
0.91
|
114
|
Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: implications for future treatment options.
|
J Acquir Immune Defic Syndr
|
2011
|
0.91
|
115
|
Assessing resistance costs of antiretroviral therapies via measures of future drug options.
|
J Infect Dis
|
2003
|
0.90
|
116
|
Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115.
|
AIDS Res Hum Retroviruses
|
2009
|
0.90
|
117
|
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
|
AIDS Patient Care STDS
|
2007
|
0.90
|
118
|
Early warning indicators for first-line virologic failure independent of adherence measures in a South African urban clinic.
|
AIDS Patient Care STDS
|
2013
|
0.90
|
119
|
Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation.
|
J Acquir Immune Defic Syndr
|
2004
|
0.89
|
120
|
Role of Baseline pol Genotype in HIV-1 Fitness Evolution.
|
J Acquir Immune Defic Syndr
|
2003
|
0.89
|
121
|
Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy.
|
J Antimicrob Chemother
|
2013
|
0.88
|
122
|
Treatment-mediated alterations in HIV fitness preserve CD4+ T cell counts but have minimal effects on viral load.
|
PLoS Comput Biol
|
2010
|
0.88
|
123
|
SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses.
|
PLoS One
|
2011
|
0.87
|
124
|
Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine.
|
Antimicrob Agents Chemother
|
2002
|
0.87
|
125
|
Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions.
|
J Clin Microbiol
|
2009
|
0.85
|
126
|
Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.
|
Antivir Ther
|
2005
|
0.85
|
127
|
Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32.
|
AIDS
|
2015
|
0.85
|
128
|
Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin.
|
Antivir Ther
|
2008
|
0.85
|
129
|
Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
|
AIDS
|
2007
|
0.84
|
130
|
Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118).
|
Antivir Ther
|
2006
|
0.84
|
131
|
Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases.
|
HIV Clin Trials
|
2011
|
0.84
|
132
|
High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998-2004.
|
AIDS
|
2007
|
0.83
|
133
|
Prevalence and clinical associations of CXCR4-using HIV-1 among treatment-naive subtype C-infected women in Botswana.
|
J Acquir Immune Defic Syndr
|
2011
|
0.83
|
134
|
Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b).
|
AIDS
|
2015
|
0.82
|
135
|
A comparison of three initial antiretroviral AIDS regimens.
|
N Engl J Med
|
2007
|
0.82
|
136
|
Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.
|
J Acquir Immune Defic Syndr
|
2013
|
0.82
|
137
|
Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study).
|
Clin Infect Dis
|
2005
|
0.82
|
138
|
Total energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome.
|
Metabolism
|
2003
|
0.82
|
139
|
Effect of the Q207D mutation in HIV type 1 reverse transcriptase on zidovudine susceptibility and replicative fitness.
|
J Acquir Immune Defic Syndr
|
2005
|
0.82
|
140
|
Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing.
|
AIDS
|
2016
|
0.82
|
141
|
Hematopoietic stem cell transplantation for HIV cure.
|
J Clin Invest
|
2016
|
0.81
|
142
|
Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.
|
PLoS One
|
2012
|
0.81
|
143
|
Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase.
|
J Acquir Immune Defic Syndr
|
2007
|
0.81
|
144
|
Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials.
|
J Acquir Immune Defic Syndr
|
2016
|
0.80
|
145
|
Report from the XV International HIV Drug Resistance Workshop.
|
AIDS Clin Care
|
2006
|
0.79
|
146
|
Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets.
|
AIDS
|
2010
|
0.79
|
147
|
Interleukin-2: trials and tribulations.
|
J Infect Dis
|
2009
|
0.79
|
148
|
Clonal CD8+ T cell expansions in peripheral blood from human immunodeficiency virus type 1-infected children.
|
J Infect Dis
|
2002
|
0.79
|
149
|
Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.
|
J Virol
|
2012
|
0.79
|
150
|
Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.
|
J Clin Microbiol
|
2006
|
0.78
|
151
|
Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia.
|
Antivir Ther
|
2014
|
0.78
|
152
|
Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.
|
Antimicrob Agents Chemother
|
2012
|
0.78
|
153
|
Two-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatment.
|
Comput Stat Data Anal
|
2009
|
0.78
|
154
|
Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial.
|
PLoS One
|
2012
|
0.78
|
155
|
Genotypic tests for determining coreceptor usage of HIV-1.
|
J Infect Dis
|
2010
|
0.77
|
156
|
Evaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruption.
|
J Acquir Immune Defic Syndr
|
2012
|
0.77
|
157
|
The future of HIV treatment.
|
J Acquir Immune Defic Syndr
|
2012
|
0.77
|
158
|
An update on HIV-1 antiretroviral resistance.
|
Curr Opin HIV AIDS
|
2006
|
0.76
|
159
|
Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel.
|
Top HIV Med
|
2003
|
0.76
|
160
|
Least among equals.
|
Clin Infect Dis
|
2012
|
0.75
|
161
|
Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen.
|
AIDS Res Ther
|
2005
|
0.75
|
162
|
Prevention of HIV-1 transmission with postexposure prophylaxis after inadvertent infected blood transfusion.
|
AIDS
|
2014
|
0.75
|
163
|
Development of dual-class antiretroviral drug resistance in a child coinfected with HIV and tuberculosis: a case report from KwaZulu-Natal, South Africa.
|
J Trop Pediatr
|
2008
|
0.75
|
164
|
When more is less.
|
Clin Infect Dis
|
2004
|
0.75
|
165
|
Report from the 2012 International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies.
|
J Watch AIDS Clin Care
|
2012
|
0.75
|
166
|
Report from the XVIII International HIV Drug Resistance Workshop.
|
J Watch AIDS Clin Care
|
2009
|
0.75
|
167
|
Report from the XVI International HIV Drug Resistance Workshop.
|
AIDS Clin Care
|
2007
|
0.75
|
168
|
Drug development strategies for salvage therapy: conflicts and solutions.
|
AIDS Res Hum Retroviruses
|
2006
|
0.75
|
169
|
A plea for justice for jailed medical workers.
|
Science
|
2006
|
0.75
|
170
|
Increased replication of HIV-1 minor variants during hematopoietic stem-cell mobilization with filgrastim.
|
J Infect Dis
|
2004
|
0.75
|
171
|
Report from the XVII International HIV Drug Resistance Workshop.
|
AIDS Clin Care
|
2008
|
0.75
|
172
|
An Abundance of Choices: Comment on "Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes".
|
Arch Intern Med
|
2012
|
0.75
|
173
|
Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.
|
J Infect Dis
|
2002
|
0.75
|
174
|
Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV.
|
PLoS Pathog
|
2017
|
0.75
|
175
|
Correction: Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa.
|
PLoS One
|
2013
|
0.75
|